Focus on Diabetes Care

Back to articles

Alogliptin: No link with increased heart failure events

KEY POINT

The use of alogliptin (Nesina—Takeda) in patients with type 2 diabetes and a recent acute coronary syndrome (ACS) event was not associated with an increased risk of heart failure–related outcomes, according to new analysis of previous trial data.